ACH
Accendra Health, Inc.
ACH trails on the overall score without a compensating advantage in the available component scores.
NVO
Novo Nordisk A/S
NVO has the edge over ACH overall, supported by stronger fundamentals.
ACH Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Stable | |
| Under pressure | |
| Weak |
ACH's profitability is currently stable, but its revenue, cash flow and balance sheet are under pressure.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
ACH PE Valuation
ACH has no meaningful PE right now: it lost money over the past year.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
ACH Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Stable | |
| Weakening | |
| Limited | |
| High |
Analysts expect ACH's earnings and profitability to decline, with its revenue holding steady.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
NVO has the edge over ACH on the outlook, with more favorable earnings and revenue expectations.
ACH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.24 | +$15.17 |
| Q2 2026 | -$3.93 | +$11.71 |
| Q1 2026 | -$14.07 | -$9.31 |
| Q4 2025 | -$14.31 | -$9.58 |
| Q3 2025 | -$17.41 | -$16.76 |
| Q2 2025 | -$15.64 | -$15.08 |
| Q1 2025 | -$4.76 | -$4.25 |
| Q4 2024 | -$4.73 | -$4.19 |
ACH is still losing money, but far less than before: $2.24 per share over the past year, against $17.41 at its worst in late 2025.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over ACH on earnings quality, reporting a profit while its opponent remains loss making.
ACH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $601.8M | -14% |
| Q2 2026 | $613.2M | -10% |
| Q1 2026 | $627.8M | -76% |
| Q4 2025 | $709M | -74% |
| Q3 2025 | $697.3M | -74% |
| Q2 2025 | $681.9M | -74% |
| Q1 2025 | $2.6B | +0.7% |
| Q4 2024 | $2.7B | +1.5% |
ACH's revenue has slid since its 2024 peak: $602M last quarter, down 14% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 0.2% | -3.6 points |
| Q2 2026 | -5.7% | +0.1 points |
| Q1 2026 | 2.7% | +2.7 points |
| Q4 2025 | 3% | +13 points |
| Q3 2025 | 3.8% | +2.9 points |
| Q2 2025 | -5.8% | -6.6 points |
| Q1 2025 | 0% | -0.4 points |
| Q4 2024 | -9.7% | -12 points |
ACH's operating margin was 0.2% last quarter, down 3.6 points from the same quarter a year ago.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over ACH on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over ACH on profitability, with a higher operating margin.
ACH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$56.6M | +$170.2M |
| Q1 2026 | -$91.7M | -$56.7M |
| Q4 2025 | $55.1M | +574% |
| Q3 2025 | -$226.8M | -$192.6M |
| Q1 2025 | -$35.1M | +$63.9M |
| Q4 2024 | $8.2M | -87% |
| Q3 2024 | -$34.2M | -132% |
| Q2 2024 | $70.3M | -73% |
ACH has burned cash in six of the last eight quarters: −$167M over the past year, against −$288M the year before.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over ACH on cash generation, producing positive trailing cash flow while its opponent burns cash.
ACH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 8.6x | High |
| Q2 2026 | 6.8x | High |
| Q1 2026 | 7.4x | High |
| Q4 2025 | 8.0x | High |
| Q1 2025 | 54.7x | High |
| Q4 2024 | 31.7x | High |
| Q3 2024 | 4.8x | High |
| Q2 2024 | 4.6x | High |
ACH's net debt is about 8.6 years of its operating earnings (EBITDA), down from more than 20 years a year ago.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO has the edge over ACH on leverage, with a lower net debt burden relative to earnings.
ACH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 24.1 | Oversold |
| Stochastic | 1.0 | Oversold |
ACH's weekly RSI is 24 (oversold) and its Stochastic is 1 (oversold).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
ACH PE vs Healthcare Sector
| Metric | ACH | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
ACH has no meaningful PE right now: it lost money over the past year.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
ACH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.34 | 56% below |
| 20 week MA | $1.44 | 90% below |
| 50 week MA | $2.21 | 93% below |
| 100 week MA | $4.90 | 97% below |
| 200 week MA | $11.4 | 99% below |
ACH is in a downtrend: it's below all five of its weekly moving averages, and 99% below its 200-week average.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has the edge over ACH on trend strength, trading above more of its moving averages.
ACH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.08 | $30.3 | +497% |
| 2021 | $30.3 | $43.7 | +44% |
| 2022 | $43.7 | $19.5 | -55% |
| 2023 | $19.5 | $19.3 | -1% |
| 2024 | $19.3 | $13.0 | -33% |
| 2025 | $13.0 | $2.77 | -79% |
| 2026 YTD | $2.77 | $0.15 | -95% |
ACH has finished four years in a row lower, and it's down 95% so far in 2026.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over ACH on returns for 2026, with the stronger performance.